![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NICE Recommends Expanded Lynparza Indication for Ovarian Cancer
NICE Recommends Expanded Lynparza Indication for Ovarian Cancer
December 13, 2019
The UK’s National Institute for Health and Care Excellence recommended AstraZeneca and Merck’s Lynparza (olaparib) for maintenance treatment of patients with relapsed, BRCA mutation ovarian, fallopian tube or peritoneal cancer whose disease has responded to platinum-based chemotherapy.
The recommendation was based on the results of a multicenter trial which showed a statistically significant improvement in progression-free survival for patients treated with olaparib compared to placebo.
The drug was previously only available to relapsed BRCAm ovarian cancer patients if they had received three or more lines of chemotherapy.
Upcoming Events
-
21Oct